Core Viewpoint - The company announced that its wholly-owned subsidiary, Federated Biotech (Zhuhai Hengqin) Co., Ltd., received FDA approval for its innovative drug UBT37034 injection, which is aimed at treating overweight or obesity [1] Drug Development - UBT37034 is a novel peptide receptor agonist that selectively targets neuropeptide Y2 receptors to aid in weight loss [1] - Preclinical studies in various animal models indicate that UBT37034, when used in conjunction with GLP-1 analogs, can significantly reduce body weight [1] Future Outlook - The company plans to continue its commitment to new product development to enhance its competitiveness and creativity in the biopharmaceutical industry [1] - The anticipated outcomes from these developments are expected to generate greater returns for the company and its shareholders [1]
联邦制药：UBT37034注射液获美国FDA新药临床试验批准